AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30387273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluency and connectedness
Number of subjects: 249
Study 28263398 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner Resources for Stress mindfulness meditation and mantra training (IR)
Number of subjects: 31
Study 28263398 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation and telephone support (PTS)
Number of subjects: 31
Study 26301648 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 31048
Study 23333007 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg twice daily
Number of subjects: 19
Study 23333007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 22308557 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (200 U or 300 U)
Number of subjects: 85
Study 22308557 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (second injection)
Number of subjects: 85
Study 22308557 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 85
Study 19293358 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa administered every week or every other week, titrated to maintain hemoglobin within +/-1.0 g/dL of baseline values, with a target range of 9.0 - 12.0 g/dL for up to 24 weeks.
Number of subjects: 73
Study 17357126 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 1
Study 17357126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 14750292 — intervention group
Group type: EXPERIMENTAL
Intervention: Student-delivered method for obtaining parental consent
Number of subjects: 1058
Study 14750292 — intervention group
Group type: COMPARATOR
Intervention: Mail method for obtaining parental consent
Number of subjects: 1058
Study 11260580 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Scheduled Toileting (IST) program
Number of subjects: 118
Study 11260580 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IST program)
Number of subjects: 118
Study 10437265 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 90
Study 10437265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 8177626 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP
Number of subjects: 80
Study 8177626 — intervention group
Group type: COMPARATOR
Intervention: DTwP
Number of subjects: 80
Study 3300565 — intervention group
Group type: COMPARATOR
Intervention: Etretinate therapy
Number of subjects: 30
Study 3300565 — intervention group
Group type: COMPARATOR
Intervention: PUVA treatment
Number of subjects: 30
Study 3300565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (PUVA + etretinate)
Number of subjects: 30
Study 29464342 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 101
Study 29464342 — intervention group
Group type: COMPARATOR
Intervention: 18-month DAPT
Number of subjects: 101
Study 27748721 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 229
Study 27748721 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil
Number of subjects: 229
Study 24814973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation combined with tracheal gas insufflation (HFO-TGI) for 8 hours
Number of subjects: 12
Study 24814973 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation combined with tracheal gas insufflation (HFO-TGI)
Number of subjects: 12
Study 24814973 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation with recruitment maneuvers (RMs) for 8 hours
Number of subjects: 12
Study 22730343 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + etanercept or MTX + hydroxychloroquine + sulfasalazine triple therapy
Number of subjects: 412
Study 22730343 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment with MTX with step-up to MTX + etanercept or to triple therapy if disease was still active at 24 weeks
Number of subjects: 412
Study 19781964 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Number of subjects: 92
Study 19781964 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline via pain-control infusion pumps (PCIP) at a flow rate of 2 mL/h for 48 h
Number of subjects: 92
Study 18431444 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-site ID regimen (0.1 ml at 4 ID sites on day 0, 0.1 ml ID at 2 sites on day 7, and at one site on days 28 and 90)
Number of subjects: 254
Study 18431444 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-site ID regimen
Number of subjects: 254
Study 18431444 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-site ID regimen (0.05 ml per ID site)
Number of subjects: 254
Study 18431444 — intervention group
Group type: COMPARATOR
Intervention: 5-dose intramuscular regimen
Number of subjects: 254
Study 16483029 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of papaverine
Number of subjects: 50
Study 16483029 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil
Number of subjects: 50
Study 12454842 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype A
Number of subjects: 258
Study 12454842 — intervention group
Group type: COMPARATOR
Intervention: Genotype F
Number of subjects: 258
Study 10508813 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiros dry powder inhaler (90- and 270-microgram albuterol base)
Number of subjects: 24
Study 10508813 — intervention group
Group type: COMPARATOR
Intervention: Ventolin metered dose inhaler (90- and 270-microgram albuterol base)
Number of subjects: 24
Study 10508813 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiros dry powder inhaler and Ventolin metered dose inhaler
Number of subjects: 24
Study 7582300 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory leukocyte protease inhibitor (SLPI)
Number of subjects: 23
Study 7582300 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight antiproteases
Number of subjects: 23
Study 7582300 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA) for SLPI
Number of subjects: 23
Study 2029994 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 102
Study 2029994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 6272429 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic climacteric women
Number of subjects: 33
Study 6272429 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic postmenopausal women
Number of subjects: 33
Study 29752008 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for 9 weeks)
Number of subjects: 253
Study 27440177 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (30 minutes once weekly for 12 consecutive weeks)
Number of subjects: 14
Study 25916959 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard settings (pulse width 210 μs, frequency 14 Hz)
Number of subjects: 11
Study 25916959 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (pulse width 90 μs, frequency 14 Hz)
Number of subjects: 11
Study 25916959 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 2-5 (pulse width and/or frequency halved or doubled)
Number of subjects: 11
Study 24619335 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h VR simulator training in the laparoscopic sigmoid colectomy module (study group)
Number of subjects: 14
Study 24619335 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 14
Study 21533812 — intervention group
Group type: EXPERIMENTAL
Intervention: AC/CAF chemotherapy
Number of subjects: 54
Study 21533812 — intervention group
Group type: COMPARATOR
Intervention: CMF chemotherapy
Number of subjects: 54
Study 19533067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast track concept in vascular surgery; introduced on May 1st 2008 with special adjustments.
Number of subjects: 0
Study 17961837 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block combined with PCA
Number of subjects: 34
Study 17961837 — intervention group
Group type: COMPARATOR
Intervention: PCA only
Number of subjects: 34
Study 17961837 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block
Number of subjects: 34
Study 15037058 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-associated dementia (HAD)
Number of subjects: 21
Study 15037058 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 21
Study 15037058 — intervention group
Group type: COMPARATOR
Intervention: Nondemented persons with HIV infection (HIV+)
Number of subjects: 21
Study 11525524 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home parenting instruction
Number of subjects: 171
Study 11525524 — intervention group
Group type: COMPARATOR
Intervention: Control group (no in-home parenting instruction)
Number of subjects: 171
Study 11525524 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention (intensive home visitation component)
Number of subjects: 171
Study 9716035 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5-FU-based chemotherapy
Number of subjects: 8
Study 2663153 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Number of subjects: 166
Study 2663153 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release formulation of trazodone, 100 mg for 1 week, followed by 200 mg or less for 3 weeks.
Number of subjects: 166
Study 2663153 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of trazodone
Number of subjects: 166
Study 2663153 — intervention group
Group type: COMPARATOR
Intervention: Controlled-release formulation of trazodone
Number of subjects: 166
Study 2663153 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 166
Study 31552779 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-induced TNF-α
Number of subjects: 117
Study 31552779 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-induced IL-6
Number of subjects: 117
Study 31552779 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-induced TNF-α + IL-6
Number of subjects: 117
Study 31552779 — intervention group
Group type: COMPARATOR
Intervention: Circulating biomarkers
Number of subjects: 117
Study 31552779 — intervention group
Group type: COMPARATOR
Intervention: Entire sample
Number of subjects: 117
Study 30468901 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion position at 60° for 24 hours after surgery without tourniquet
Number of subjects: 100
Study 30468901 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet use with the same flexion position as Group A
Number of subjects: 100
Study 26719401 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG + CRT
Number of subjects: 178
Study 26719401 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 178
Study 25496446 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture Group (AG) - electroacupuncture at sub-specific points (Shaoyang meridians, Luxi (TE19), San Yangluo (TE8), Xi Yangguan (GB33))
Number of subjects: 30
Study 25496446 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture Group (SAG) - non-acupoints stimulation
Number of subjects: 30
Study 25496446 — intervention group
Group type: COMPARATOR
Intervention: Migraine Group (MG) - no treatment
Number of subjects: 30
Study 23157714 — intervention group
Group type: EXPERIMENTAL
Intervention: Trunk Release Maneuver (TRM)
Number of subjects: 117
Study 23157714 — intervention group
Group type: COMPARATOR
Intervention: Standard High Fowler's position (Control)
Number of subjects: 117
Study 20535581 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Capsule (XFZY)
Number of subjects: 90
Study 20535581 — intervention group
Group type: COMPARATOR
Intervention: Shengmai Capsule (SM)
Number of subjects: 90
Study 20535581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 18272546 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalazine 2.4 g/day (once-daily dosing)
Number of subjects: 174
Study 18272546 — intervention group
Group type: EXPERIMENTAL
Intervention: MMX mesalazine 2.4 g/day (twice-daily dosing)
Number of subjects: 174
Study 14999298 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-7 (daunorubicin 60 mg/m2/day, days 1-3; cytarabine 200 mg/m2/day, days 1-7; cladribine 5 mg/m2/day, days 1-5)
Number of subjects: 400
Study 14999298 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-7
Number of subjects: 400
Study 14999298 — intervention group
Group type: COMPARATOR
Intervention: DA-7 (without cladribine)
Number of subjects: 400
Study 14999298 — intervention group
Group type: COMPARATOR
Intervention: DA-7
Number of subjects: 400
Study 11429349 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 69
Study 11429349 — intervention group
Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 69
Study 9511845 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference group (subjects choose their treatment)
Number of subjects: 0
Study 9511845 — intervention group
Group type: COMPARATOR
Intervention: Randomized group (random allocation to treatment)
Number of subjects: 0
Study 8276667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary application with total reference air kerma
Number of subjects: 0
Study 8276667 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference isodose surface
Number of subjects: 0
Study 2848053 — intervention group
Group type: EXPERIMENTAL
Intervention: CORT (500 mg bolus injection within 5 s of the start of surgery)
Number of subjects: 30
Study 2848053 — intervention group
Group type: EXPERIMENTAL
Intervention: FENT (50-100 mg)
Number of subjects: 30
Study 2848053 — intervention group
Group type: EXPERIMENTAL
Intervention: CORT (500 mg bolus injection) + FENT (50-100 mg)
Number of subjects: 30
Study 2848053 — intervention group
Group type: COMPARATOR
Intervention: No CORT, No FENT (Group I)
Number of subjects: 30
Study 30727856 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy in core-too-large patients
Number of subjects: 71
Study 30727856 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy in NIHSS 6 to 9 group
Number of subjects: 71
Study 29076318 — intervention group
Group type: EXPERIMENTAL
Intervention: PDRN (5.625 mg, 3 mL, intramuscular 5 days a week and perilesional 2 days a week)
Number of subjects: 20
Study 29076318 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (3 mL)
Number of subjects: 20
Study 26421852 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive e-learning module on appropriate imaging referrals for pulmonary embolism
Number of subjects: 0
Study 26421852 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive e-learning module on cervical spine trauma
Number of subjects: 0
Study 26421852 — intervention group
Group type: COMPARATOR
Intervention: Static versions of CDRs
Number of subjects: 0
Study 22831853 — intervention group
Group type: EXPERIMENTAL
Intervention: TOCAS 0.4 mg plus SOLI 6 mg
Number of subjects: 0
Study 22831853 — intervention group
Group type: EXPERIMENTAL
Intervention: TOCAS 0.4 mg plus SOLI 9 mg
Number of subjects: 0
Study 22831853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22333618 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) treatment with PBMC culture
Number of subjects: 58
Study 22333618 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-thymectomy PBMC
Number of subjects: 58
Study 22333618 — intervention group
Group type: COMPARATOR
Intervention: Purified protein derivative (PPD) test
Number of subjects: 58
Study 19922649 — intervention group
Group type: EXPERIMENTAL
Intervention: Digestive Advantage Gas Defense Formula (GanedenBC30 Bacillus coagulans GBI‐30, 6086)
Number of subjects: 61
Study 19922649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16803740 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST) delivered by Master's trained social workers in a primary care setting
Number of subjects: 0
Study 16803740 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 15000548 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 120
Study 15000548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehearsal
Number of subjects: 120
Study 15000548 — intervention group
Group type: COMPARATOR
Intervention: Control (freely chosen strategy)
Number of subjects: 120
Study 11103184 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% gelatin
Number of subjects: 60
Study 11103184 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% low‐molecular weight (LMW) hydroxyethyl starch (HES)
Number of subjects: 60
Study 11103184 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% medium‐molecular weight (MMW) HES
Number of subjects: 60
Study 11103184 — intervention group
Group type: COMPARATOR
Intervention: All groups (4% gelatin, 6% LMW HES, 6% MMW HES)
Number of subjects: 60
Study 9350665 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood side standard method for eKt/V
Number of subjects: 35
Study 9350665 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate side measurements
Number of subjects: 35
Study 9350665 — intervention group
Group type: COMPARATOR
Intervention: Single-sample intradialysis method
Number of subjects: 35
Study 9350665 — intervention group
Group type: COMPARATOR
Intervention: Multiple-sample intradialysis method
Number of subjects: 35
Study 9350665 — intervention group
Group type: COMPARATOR
Intervention: Rate method
Number of subjects: 35
Study 9350665 — intervention group
Group type: COMPARATOR
Intervention: All four alternative methods
Number of subjects: 35
Study 8349933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized cat extract (total dose approximately 4,500,000 allergy units)
Number of subjects: 41
Study 8349933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 8349933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized cat extract
Number of subjects: 41
Study 3954442 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal bracing using a rigid supporting jacket
Number of subjects: 40
Study 3954442 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from sitting to supine position
Number of subjects: 40
Study 31927499 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT) for 3 weeks
Number of subjects: 54
Study 31927499 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 54
Study 31927499 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 54
Study 30517724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation (VAS) of 10,000 IU weekly until 6 mo postpartum
Number of subjects: 112
Study 30517724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 27550645 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycystic kidney disease cohort
Number of subjects: 4346
Study 27550645 — intervention group
Group type: COMPARATOR
Intervention: Control non-policystic kidney disease cohort
Number of subjects: 4346
Study 24882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt intervention (sleep education program)
Number of subjects: 152
Study 24882907 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 152
Study 21881597 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg atorvastatin
Number of subjects: 50
Study 21881597 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 20708076 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucoadhesive tablet containing 24 μg clobetasol‐17 propionate (CP) applied 3 times a day for 4 weeks
Number of subjects: 16
Study 20708076 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial CP ointment for cutaneous application (123 μg/application) mixed with Orabase™
Number of subjects: 16
Study 20708076 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 16
Study 18534050 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg once daily for 28 days
Number of subjects: 419
Study 18534050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 14660211 — intervention group
Group type: EXPERIMENTAL
Intervention: PErforM program (Experimental group)
Number of subjects: 117
Study 14660211 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 11443835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status assessment using Subjective Global Assessment
Number of subjects: 374
Study 11443835 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for malnutrition
Number of subjects: 374
Study 11443835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional screening and/or assessment
Number of subjects: 374
Study 9051558 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg three times daily for 10 days)
Number of subjects: 186
Study 9051558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 8391756 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella abortus equi endotoxin (0.4 ng/kg body wt)
Number of subjects: 15
Study 8391756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3085560 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 60
Study 3085560 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 60
Study 3085560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of epinephrine and aminophylline
Number of subjects: 60
Study 3085560 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 31356228 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m (C20)
Number of subjects: 35
Study 28574378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study 28574378 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0